Therefore, regardless of BRAF mutations, treatment with targeted therapies or chemotherapeutic agents for melanoma increases FAO as a defense mechanism, thereby increasing ATP production and significantly supporting melanoma survival. The gene discussed is BRAF; the disease is melanoma.